Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...
The accident that took place at Fukushima Daiichi has fundamentally changed the nuclear power sector and its approach to safety. Experiences and lessons learned from the accident, as well as ...
The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...
Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.
The flying drone to be used at Fukushima Daiichi’s Unit 1 building. (Credit: Daisuke Kojima/Kyodo News via AP) These flying drones are 20 cm across, weigh 185 grams each, and were adapted from ...
Back in 2011, the world held its breath after the Fukushima Daiichi nuclear plant in Japan suffered a failure of its cooling systems, in the wake of the country getting hit by a 9.0 magnitude ...
Details for this discharge can be found on TEPCO’s webpage. Green – a numerical value and a green dot indicate that this aspect of the discharge system is operating currently and that the data being ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Dai-ichi Life Insurance Co. announced on Oct. 29 it will lower the estimated rate of return for the defined benefit corporate pension insurance policies it has contracted with about 3,000 ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...